FrancophonIA/ELRC3.0 huggingface dataset:
English: In addition, given the lack of evidence regarding the optimal duration of bisphosphonate treatment for osteoporosis, and considering that duration of treatment is a risk factor for atypical femoral fractures, the CHMP also recommended that information should be added to section 4.2. of the product information for bisphosphonates authorised for osteoporosis, about the need to periodically evaluate the need for continuing bisphosphonate treatment, particularly after 5 years of treatment, on an individual patient basis.
Estonian: Arvestades ka seda, et ei ole tõendatud, milline on bisfosfonaatide kasutamise optimaalne kestus osteoporoosi ravis ning ravi jätkamine on atüüpiliste reieluumurdude riskifaktor, soovitas inimravimite komitee, et ravimiteabe lõiku 4.2 tuleb lisada osteoporoosi raviks kinnitatud bisfosfonaatide kohta teave regulaarselt hinnata bisfosfonaatide ravi jätkamise vajadust, eriti pärast 5 aasta pikkust ravi, tehes seda igal üksikjuhul eraldi.
English: Following a Pharmacovigilance Working Party (PhVWP) review in 2008, it was concluded that a warning about atypical stress fractures of the proximal femoral shaft would be added to the product information for alendronic acid containing medicinal products across Europe.
Estonian: Ravimiohutuse järelevalve töörühma 2008. a analüüsi põhjal tehti otsus, et alendroonhapet sisaldavate ravimite ravimiteabesse tuleb kogu Euroopa Liidus lisada hoiatus reieluu diafüüsi proksimaalse osa atüüpiliste stressmurdude kohta.
English: Schilcher J et al Incidence of stress fractures of the femoral shaft in women treated with bisphosphonates.
Estonian: Accessed 15 February 2011 14 Schilcher J et al Incidence of stress fractures of the femoral shaft in women treated with bisphosphonates.
English: J Bone Miner Res 25 (Suppl 1) 2010; Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=223582c5-f5bb-4d66-bd16d073267b2a47.
Estonian: J Bone Miner Res 25 (Suppl 1) 2010; Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=223582c5-f5bb-4d66-bd16
English: Although pre-clinical studies have provided limited information on the risk of atypical fractures with bisphosphonates, some of them have demonstrated that suppression of bone turnover by bisphosphonates may increase microdamage accumulation and the accumulation of advanced glycation end-products resulting in changes in the biomechanical properties of bone (Brennan et al, 2011, Hofstaetter et al, 2010, Mashiba et al, 2000, O'Neal et al, Tang et al, 20091).
Estonian: Kuigi prekliinilistes uuringutes on teavet atüüpilistest luumurdudest bisfosfonaatide kasutamisel piiratud hulgal, on mõned uuringud näidanud, et bisfosfonaatide tekitatav luuloome pärssimine võib suurendada mikrokahjustuste akumuleerumist ja suhkrumolekulide liitumist valkude või rasvhapetega, põhjustades muutusi luu biomehaanilistes omadustes (Brennan et al, 2011, Hofstaetter et al, 2010, Mashiba et al, 2000, O'Neal et al, Tang et al, 20091).
English: Concomitant treatment with other anti-resorptive drugs such as hormone replacement therapy and raloxifene have also been proposed as possible risk factors.
Estonian: Võimalike riskifaktoritena on välja toodud samaaegne ravi teiste antiresorptiivsete ravimitega (näiteks hormoonasendusravi) ja raloksifeeniga.
English: Other studies with radiographic evidence have also reported an increased incidence of atypical femoral fractures in patients treated with bisphosphonates compared to non-exposed patients, which may increase with duration of bisphosphonate treatment (Dell et al, 201013, Schilcher et al, 200914).
Estonian: Teistes radioloogilise tõendusega uuringutes on samuti teateid suurenenud atüüpiliste reieluumurdude sagedamast esinemisest bisfosfonaatidega ravitud patsientidel võrreldes bisfosfonaatidega mitte kokku puutunud patsientidega, kusjuures selliseid murde võib bisfosfonaatide ravi kestmisel rohkem esineda (Dell et al, 201013, Schilcher et al, 200914).
English: The task force of the American Society for Bone and Mineral Research (ASBMR) on atypical subtrochanteric and diaphyseal femoral fractures have defined major and minor features of atypical femoral fracture (Shane et al, 20103) and recommend that for a case to be considered an atypical femoral fracture all major features need to be present, whereas the minor features have commonly been described in cases of atypical femoral fractures, but are not present in all patients.
Estonian: Ameerika luu- ja mineraalide uuringu ühingu (American Society for Bone and Mineral Research , ASBMR) atüüpiliste reieluu pöörli ja diafüüsi murdude töökond määratles atüüpiliste reieluumurdude põhilised ja vähemtähtsad tunnused (Shane et al, 20103) ning soovitas atüüpilise reieluumurru liigitamisel pidada oluliseks kõigi põhiliste tunnuste esinemist.
English: Glucocorticoids and proton pumps inhibitor (PPI) have been identified as possible important risk factors for atypical femur fracture.
Estonian: On leitud, et glükokortikoidide ja prootonpumba inhibiitorite (PPI) kasutamine võib olla atüüpiliste reieluumurdude tähtis riskifaktor.
English: The potential risk of atypical fractures at sites other than the femur will be kept under review.
Estonian: Muude luude kui reieluu võimalike atüüpiliste murdude riski jälgitakse edasi.
English: Casecontrol studies have reported a significant association between atypical femur fracture pattern and bisphosphonate use (Lenart et al, 200911, Isaacs et al, 201012).
Estonian: Juhtumipõhistest uuringutest on teateid olulistest seostest atüüpilise reieluumurru vormi ja bisfosfonaatide kasutamise vahel (Lenart et al, 200911, Isaacs et al, 201012).
English: Annex II Scientific conclusions and grounds for amendment of the summaries of product characteristics and package leaflets presented by the EMA
Estonian: II lisa Euroopa Ravimiameti esitatud teaduslikud järeldused ning ravimi omaduste kokkuvõtete ja pakendi infolehtede muutmise alused
English: Accessed 5 April 2011
Estonian: 2007 to 2009.
English: The mechanism(s) for the development of atypical fractures in patients taking bisphosphonates is not known.
Estonian: Atüüpiliste luumurdude tekkemehhanism(id) bisfosfonaate manustavatel patsientidel ei ole teada.
English: However a number of possible mechanisms of atypical fracture in association with bisphosphonate use have been postulated.
Estonian: Atüüpiliste luumurdude võimalike mehhanismide kohta seoses bisfosfonaatide kasutamisega on tehtud mitmeid oletusi.
English: • Addition of atypical femoral fracture to section 4.8 (Undesirable effects) of the SmPC accompanied by a statement that this adverse effect is a class attribution of all bisphosphonates.
Estonian: • Lisada ravimi omaduste kokkuvõtte lõiku 4.8 (Kõrvaltoimed) atüüpiline reieluumurd ja viide, et see kõrvaltoime iseloomustab kogu bisfosfonaatide rühma.
English: Non-clinical data
Estonian: Mittekliinilised andmed
English: The number of post-marketing reports of possible atypical femur fracture suspected to be associated with bisphosphonates has increased since the 2008 PhVWP review.
Estonian: Pärast 2008. a ravimiohutuse järelevalve töörühma analüüsi on esinenud rohkem müügiloa väljastamise järgseid teateid, milles kahtlustatakse atüüpiliste reieluumurdude võimalikku seost bisfosfonaatidega.
English: Lenart BA et al Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.
Estonian: J Bone Miner Res 2011; DOI 10.1002/jbmr.233 11 Lenart BA et al Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.
English: 7 Abrahamsen B et al Cumulative alendronate dose and the long term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
Estonian: J Bone Miner Res 2009; 24: 1095-1102 7 Abrahamsen B et al Cumulative alendronate dose and the long term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort study.
English: • Addition of a warning in section 4.4 of the SmPC (Special warnings and precautions for use) to reflect this risk , the main features of these fractures and the potential need for discontinuation of treatment in case a fracture is suspected.
Estonian: • Lisada ravimi omaduste kokkuvõtte lõiku 4.4 (Hoiatused ja ettevaatusabinõud kasutamisel) hoiatus,
English: A number of possible risk factors have been proposed for atypical femoral fractures in association with bisphosphonate use.
Estonian: Seoses bisfosfonaatide kasutamisega on atüüpiliste reieluumurdude kohta pakutud mitmeid võimalikke riskifaktoreid.
English: The lack of evidence may be due to a lack of recognition and reporting of atypical fractures at sites other than the femur with bisphosphonate use or it is possible that the unique characteristics of the femur as the major weight bearing bone in the body mean that atypical fractures only occur at this site.
Estonian: Teine võimalus on, et reieluude kui peamiste keharaskust kandvate luude unikaalsete omaduste tõttu toimuvad atüüpilised luumurrud just neis.
English: Dell R et al A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009.
Estonian: Relat Res 2010; 468: 3384-3392 13 Dell R et al A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years
English: Hofstaetter JG et al.
Estonian: Clin Orthop
English: Vestergaard P et al Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.
Estonian: J Clin Endocrinol Metab 2010; 95:5258-5265 8 Vestergaard P et al Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.
English: 12 Isaacs JD et al Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.
Estonian: Osteoporos Int 2009; 20: 1353-1362 12 Isaacs JD et al Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.
English: You can take them with or without food.
Estonian: Te võite võtta neid koos toiduga või ilma.
English: Date of first authorisation: 21 February 2008 Date of first renewal: 19 November 2012
Estonian: Müügiloa esmase väljastamise kuupäev: 21. veebruar 2008 Müügiloa viimase uuendamise kuupäev: 19. november 2012
English: Ask your pharmacist how to throw away medicines no longer required.
Estonian: Küsige oma apteekrilt, kuidas visata ära ravimeid, mida te enam ei kasuta.
English: • Do you need to receive vaccines (live vaccines)?
Estonian: • Kas teile on vaja manustada vaktsiine (elusvaktsiine)?
English: • You are a child or teenager who has not started having periods.
Estonian: • te olete laps või teismeline, kellel ei ole veel menstruatsioonid alanud.
English: It is important not to take too many capsules.
Estonian: Oluline on mitte võtta liiga palju kapsleid.
English: Talk to your doctor immediately,
Estonian: Pidage otsekohe nõu oma arstiga:
English: • changes in different laboratory parameters
Estonian: • muutused erinevates laboratoorsetes näitajates
English: Your treatment is started and monitored by a doctor who is specialised in transplants.
Estonian: Teie ravi alustatakse ja jälgitakse arsti poolt, kes on spetsialiseerunud organite siirdamisele.
English: 50 tablets 150 tablets 50 x 1 tablets
Estonian: 50 tabletti 150 tabletti 50 x 1 tabletti
English: There are limited safety and efficacy data in children below the age of 2°years.
Estonian: Alla 2-aastaste laste kohta on ohutus- ja efektiivsusandmeid vähe.
English: It is important not to take too many tablets.
Estonian: Oluline on mitte võtta liiga palju tablette.
English: 100 capsules 300 capsules 100 x 1 capsules
Estonian: 100 kapslit 300 kapslit 100 x 1 kapslit
English: Hepatic transplant patients were followed for at least 1°year, but less than 3°years.
Estonian: Maksatransplantaadiga patsiente jälgiti vähemalt 1 aasta jooksul, kuid vähem kui 3 aastat.
English: It is important to take the medicine for as long as the doctor has told you to.
Estonian: Oluline on võtta ravimit nii kaua, nagu arst on teile rääkinud.
English: • serious infection which may affect the whole body
Estonian: • raske nakkus, mis võib haarata kogu organismi
English: Your doctor will have to advise you what is indicated for you.
Estonian: Teie arst peab andma nõu, mis on teile näidustatud.
English: Information concerning the following antibiotics is available:
Estonian: Olemas on teave järgmiste antibiootikumide kohta.
English: If you forget to take your medicine at any time, take it as soon as you remember, then continue to take it at the usual times.
Estonian: Kui te unustate mistahes ajal oma ravimit manustada, siis võtke see sisse niipea kui teile meenub.
English: • Septum pellucidum agenesis;
Estonian: • septum pellucidum'i agenees;
English: Children and adolescents (aged 2 to 18)
Estonian: Lapsed ja noorukid (2...18-aastased)
English: These patients should also be carefully observed.
Estonian: Neid patsiente tuleb ravi ajal hoolikalt jälgida.
English: The proportion of patients with CMV viraemia/syndrome was 13.5%.
Estonian: CMV-vireemia/sündroomiga patsientide hulk oli 13,5%.
English: The dose given will vary depending on the size of the child.
Estonian: Lapsele määratud annus oleneb lapse suurusest.
English: Povidone K-30
Estonian: Povidoon K-30
English: • You have sex without using an effective method of contraception.
Estonian: • te olete seksuaalvahekorras ilma efektiivset rasestumisvastast vahendit kasutamata.
English: EU/1/07/438/003 (50 tablets) EU/1/07/438/004 (150 tablets) EU/1/07/438/005 (50 x 1 tablets)
Estonian: EU/1/07/438/003 (50 tabletti) EU/1/07/438/004 (150 tabletti) EU/1/07/438/005 (50 x 1 tabletti)
English: • if you are breast-feeding.
Estonian: • kui te toidate rinnaga.
English: The patient information pack should contain:
Estonian: Patsiendi infopaketis peavad sisalduma:
English: • You are post-menopausal, i.e. at least 50 years old and your last period was more than a year ago (if your periods have stopped because you have treatment for cancer, then there is still a chance you could become pregnant).
Estonian: • te olete menopausi läbinud, st vähemalt 50 aasta vanune ning teie viimane menstruatsioon oli rohkem kui aasta tagasi (kui menstruatsioonid on ära jäänud vähiravi tõttu, esineb siiski rasestumise võimalus).
English: It is used in combination with other medicines with a similar function (i.e. ciclosporin and corticosteroids).
Estonian: Seda kasutatakse kombinatsioonis teiste ravimitega, millel on sarnane funktsioon (st tsüklosporiin ja kortikosteroidid).
English: Do not crush the tablets.
Estonian: Ärge purustage tablette.
English: Non-melanoma skin carcinomas occurred in 3.6% of patients; other types of malignancy occurred in 1.1% of patients.
Estonian: Nahakartsinoomid (mitte-melanoomid) tekkisid 3,6% patsientidest, muud tüüpi pahaloomulisi kasvajaid tekkis 1,1% patsientidest.
English: See also further information in this section under “Warnings and precautions” and “Pregnancy, contraception and breast-feeding”.
Estonian: Vt ka lisateave antud lõigus pealkirjade „Hoiatused ja ettevaatusabinõud“ ning „Rasedus, rasestumisvastased vahendid ja imetamine“ all.
English: The health professional educational material should contain:
Estonian: Tervishoiutöötaja teavitusmaterjal peab sisaldama:
English: Contraception (see section 4.6)
Estonian: Rasestumisvastased vahendid (vt lõik 4.6)
English: Contact your doctor as soon as possible, if you think your contraception may not have been effective or if you have forgotten to take your contraceptive pill.
Estonian: Võtke niipea kui võimalik ühendust oma arstiga, kui arvate, et rasestumisvastane vahend ei pruugi olla tõhus või kui olete unustanud rasestumisvastase pilli võtmata.
English: Other medicines and Myfenax
Estonian: Muud ravimid ja Myfenax
English: This effect tended to diminish with continued antibiotic use and to cease within a few days of antibiotic discontinuation.
Estonian: See toime nõrgenes antibiootikumide jätkuva kasutamise käigus ning kadus mõne päeva jooksul pärast antibiootikumide ärajätmist.
English: EU/1/07/438/001 (100 capsules) EU/1/07/438/002 (300 capsules) EU/1/07/438/006 (100 x 1 capsules)
Estonian: EU/1/07/438/001 (100 kapslit) EU/1/07/438/002 (300 kapslit) EU/1/07/438/006 (100 x 1 kapslit)
English: Hypotension, hypertension, vasodilatation
Estonian: Hüpotensioon, hüpertensioon, vasodilatatsioon
English: • You miss or think you have missed a period, or you have unusual menstrual bleeding, or suspect you are pregnant.
Estonian: • teil jääb menstruatsioon vahele või te arvate, et teil on menstruatsioon vahele jäänud, või teil tekib ebatavaline menstruaalverejooks või te kahtlustate rasedust;
English: • You were born with one of the following rare conditions that make pregnancy impossible: the XY genotype, Turner`s syndrome or uterine agenesis.
Estonian: • teil esineb üks järgmistest harvaesinevatest kaasasündinud seisunditest, mille tõttu ei ole rasestumine võimalik: XY-genotüüp, Turneri sündroom või emaka agenees
English: Hypromellose (HPMC 2910) Titanium dioxide (E171) Macrogol (PEG 400) Talc
Estonian: Hüpromelloos (HPMC 2910) Titaandioksiid (E171) Makrogool (PEG 400) Talk
English: • You plan to become pregnant.
Estonian: • te kavatsete rasestuda;
English: Do not stop taking Myfenax because you feel better.
Estonian: Ärge lõpetage Myfenax'i võtmist, kui te tunnete ennast paremini.
English: It is recommended, however, to administer Myfenax at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption of MPA.
Estonian: Siiski soovitatakse Myfenax'i manustada vähemalt üks tund enne või kolm tundi pärast sevelameeri manustamist, et viia miinimumini mõju MFH imendumisele.
English: • decrease in the amount of antibodies in the blood
Estonian: • antikehade arvu vähenemine veres
English: • you have black or bloody stool or if you vomit blood or dark particles that look like coffee grounds.
Estonian: • teie väljaheide on musta värvi või verine või kui te oksendate verd või kohvipaksu meenutavaid tumedaid osakesi.
English: The educational programme is aimed at ensuring that the health professionals and patients are aware of the teratogenicity and mutagenicity, the need for pregnancy tests before starting therapy with Myfenax, the contraceptive requirements for both male and female patients and what to do in case of pregnancy during treatment with Myfenax.
Estonian: Teavitusprogrammi eesmärk on tagada tervishoiutöötajate ja patsientide teadlikkus teratogeensusest ja mutageensusest, rasedustestide tegemise vajadusest enne Myfenax'iga ravi alustamist, rasestumisvastaste vahendite kasutamise nõuetest nii mees- kui naispatsientidele ning mida teha, kui Myfenax -ravi ajal leiab aset rasestumine.
English: • Your fallopian tubes and both ovaries have been removed by surgery (bilateral salpingooophorectomy).
Estonian: • teie munajuhad ja mõlemad munasarjad on kirurgiliselt eemaldatud (kahepoolne salpingoooforektoomia).
English: • Your ovaries no longer work (premature ovarian failure, which has been confirmed by a specialist gynaecologist).
Estonian: • teie munasarjade talitlus on lakanud (enneaegne munasarjade puudulikkus, mida on kinnitanud spetsialist-günekoloog)
English: • low/high blood pressure, widening of blood vessels
Estonian: • madal/kõrge vererõhk, veresoonte laienemine
English: • For 6°weeks after you stop taking Myfenax.
Estonian: • 6 nädalat pärast seda, kui lõpetate Myfenax'i võtmise.
English: Swallow your capsules whole with a glass of water.
Estonian: Neelake kapslid alla koos klaasitäie veega.
English: Myfenax is a medicine that is used to suppress immune activity.
Estonian: Myfenax on ravim, mida kasutatakse immuunsuse aktiivsuse pärssimiseks.
English: Swallow your tablets whole with a glass of water.
Estonian: Neelake tabletid alla koos klaasitäie veega.
English: Myfenax is an inosine monophosphate dehydrogenase (IMPDH) inhibitor.
Estonian: Myfenax on inosiinmonofosfaadi dehüdrogenaasi (IMPDH) inhibiitor.
English: What Myfenax is and what it is used for What you need to know before you take Myfenax How to take Myfenax
Estonian: Mis ravim on Myfenax ja milleks seda kasutatakse Mida on vaja teada enne Myfenax'i võtmist Kuidas Myfenax'i võtta
English: It is recommended to monitor MPA exposure levels and to adjust Myfenax doses accordingly to maintain clinical efficacy when rifampicin is administered concomitantly.
Estonian: Soovitatav on jälgida MFH ekspositsiooni väärtusi ja kohandada vastavalt Myfenax'i annuseid, et säilitada kliiniline efektiivsus rifampitsiini samaaegsel manustamisel.
English: MPA AUC values across age groups were similar in the early and late post-transplant period.
Estonian: MFH AUC väärtused on erinevates vanusegruppides sarnased nii varases kui ka hilises transplantatsioonijärgses perioodis.
English: • if you are not using effective contraception (see Pregnancy, contraception and breast-feeding).
Estonian: • kui te ei kasuta efektiivsett rasestumisvastast vahendit (vt „Rasedus, rasestumisvastased vahendid ja imetamine“);
English: • high level of potassium in the blood, low level of potassium, magnesium, calcium and/or phosphate in the blood
Estonian: • kõrge kaaliumisisaldus veres, madal kaaliumi-, magneesiumi-, kaltsiumi ja/või fosfaadisisaldus veres
English: • if you are planning to become pregnant, or if you get pregnant while taking Myfenax.
Estonian: • kui te planeerite rasedust või rasestute Myfenax'i võtmise ajal.
English: However, at high MPAG plasma concentrations (>°100 µg/mL), small amounts of MPAG are removed.
Estonian: MFHG suurte kontsentratsioonide korral (> 100 μg/ml) on selle väiksed kogused siiski eemaldatavad.
English: Agranulocytosis (≥1/1000 to <1/100) and neutropenia have been reported; therefore regular monitoring of patients taking Myfenax is advised (see section 4.4).
Estonian: Kirjeldatud on agranulotsütoosi (≥ 1/1000...< 1/100) ja neutropeeniat, mistõttu on soovitatav Myfenax'i kasutavate patsientide regulaarne jälgimine (vt lõik 4.4).
English: Avoid contact with any powder that spills out from damaged capsules.
Estonian: Vältige kokkupuudet kahjustunud kapslist välja tulnud pulbriga.
English: Very common (may affect more than 1 in 10 people)
Estonian: Väga sage (võib esineda rohkem kui 1-l kasutajal 10-st)
English: In contrast, if concomitant ciclosporin treatment is stopped, an increase in MPA AUC of around 30% should be expected.
Estonian: Ent kui samaaegne tsüklosporiinravi lõpetatakse, on oodata MFH AUC suurenemist ligikaudu 30% võrra.
English: • you have a rash, swelling of your face, lips, tongue or throat, with difficulty breathing - you may be having a serious allergic reaction to the medicine (such as anaphylaxis, angioeodema).
Estonian: • teil tekib lööve; näo-, huulte, keele- või kõriturse koos hingamisraskusega: teil võib olla tõsine allergiline reaktsioon (nt anafülaksia, angioödeem) ravimile;
English: • Guide for healthcare professionals
Estonian: • Juhend tervishoiutöötajatele.
English: Contents of the pack and other information What Myfenax contains
Estonian: Pakendi sisu ja muu teave Mida Myfenax sisaldab
English: These may be signs of bleeding in the stomach or intestines.
Estonian: Need võivad olla mao või soolte verejooksu nähud.
English: However, MPA Cmax was decreased by 40% in the presence of food.
Estonian: Siiski vähenes MFH Cmax ravimi koos söögiga tarvitamisel 40% võrra.
English: Hepatitis, jaundice, hyperbilirubinaemia
Estonian: Hepatiit, ikterus, hüperbilirubineemia
English: Patients should be advised that during treatment with Myfenax, vaccinations may be less effective and the use of live attenuated vaccines should be avoided (see section 4.5).
Estonian: Patsiente tuleb teavitada, et ravi ajal Myfenax'iga võib vaktsineerimiste efektiivsus olla vähenenud ja elustekitajat sisaldavate vaktsiinide kasutamist tuleks vältida (vt lõik 4.5).
English: MPA at clinically relevant concentrations is 97% bound to plasma albumin.
Estonian: Kliiniliselt oluliste kontsentratsioonide juures seondub 97% MFH-st plasma albumiinidega.
English: Medicinal products that interfere with enterohepatic circulation (e.g. cholestyramine, ciclosporin A, antibiotics)
Estonian: Enterohepaatilist tsirkulatsiooni mõjutavad ravimid (nt kolestüramiin, tsüklosporiin A, antibiootikumid)